DBV Technologies (NASDAQ:DBVT) Shares Pass Below 50-Day Moving Average - Here's What Happened

Key Points

• DBV Technologies' stock price has fallen below its fifty-day moving average of $9.81, closing at $9.79 with a trading low of $9.61.
• Analysts have mixed views on the stock, with ratings ranging from "strong buy" to "sell" and a consensus price target of $14.75.
• The company reported a quarterly loss of ($1.55) EPS, significantly missing analyst expectations, although revenue surpassed estimates with $1.74 million.

DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report) passed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $9.81 and traded as low as $9.61. DBV Technologies shares last traded at $9.79, with a volume of 13,267 shares changing hands.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on DBVT. Lifesci Capital upgraded DBV Technologies to a "strong-buy" rating in a research report on Thursday, June 26th. JMP Securities restated a "market outperform" rating and issued a $21.00 price objective on shares of DBV Technologies in a report on Thursday, June 26th. Citigroup reissued an "outperform" rating on shares of DBV Technologies in a research note on Tuesday, May 27th. The Goldman Sachs Group raised shares of DBV Technologies to a "sell" rating and set a $7.25 target price on the stock in a research note on Thursday, May 29th. Finally, Wall Street Zen lowered shares of DBV Technologies from a "hold" rating to a "sell" rating in a research note on Friday, July 18th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, DBV Technologies currently has an average rating of "Moderate Buy" and an average price target of $14.75.

DBV Technologies Price Performance

The business's 50 day simple moving average is $9.80 and its 200 day simple moving average is $8.20. The company has a market capitalization of $262.40 million, a PE ratio of -2.01 and a beta of -0.36.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last issued its earnings results on Tuesday, July 29th. The company reported ($1.55) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by ($1.34). The firm had revenue of $1.74 million for the quarter, compared to analysts' expectations of $0.64 million. DBV Technologies had a negative return on equity of 287.15% and a negative net margin of 3,220.49%. As a group, analysts anticipate that DBV Technologies S.A. will post -7.05 EPS for the current year.

Institutional Investors Weigh In On DBV Technologies

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DBVT. Nan Fung Trinity HK Ltd. purchased a new stake in shares of DBV Technologies in the 2nd quarter valued at approximately $340,000. Octagon Capital Advisors LP purchased a new stake in DBV Technologies in the second quarter valued at approximately $9,315,000. MPM Bioimpact LLC purchased a new stake in DBV Technologies in the second quarter valued at approximately $9,649,000. Adage Capital Partners GP L.L.C. purchased a new stake in DBV Technologies in the second quarter valued at approximately $9,659,000. Finally, Vivo Capital LLC purchased a new stake in DBV Technologies in the second quarter valued at approximately $9,659,000. Hedge funds and other institutional investors own 71.74% of the company's stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.